PR Newswire
WILMINGTON, Del., Feb. 17, 2026
Rising prevalence of transfusion-dependent anemias, increasing awareness of iron overload complications, and growing preference for oral iron chelation therapies are the major factors which drive the global deferiprone market growth.
WILMINGTON, Del., Feb. 17, 2026 /PRNewswire/ — Allied Market Research published a report, titled, «Deferiprone Market by Form (Tablets and Others), Application (Transfusional Iron Overload and NTDT Caused Overload.), and Distribution Channel (Hospital Pharmacies, Drug store & retail pharmacies and Online providers): Global Opportunity Analysis and Industry Forecast, 2024-2033». According to the report, the deferiprone market was valued at $33.4 million in 2023, and is estimated to reach $45.9 million by 2033, growing at a CAGR of 3.2% from 2024 to 2033.
http://mma.prnewswire.com/media/636519/5801121/Allied_Market_Research_Logo.jpg
Request Sample of the Report on Global Deferiprone Market 2033 –
https://www.alliedmarketresearch.com/request-sample/A324401
Prime Determinants of Growth
The increasing prevalence of transfusion-dependent disorders such as beta-thalassemia and sickle cell disease, rising awareness regarding iron overload complications, and growing preference for oral iron chelation therapies are the major factors that drive the growth of the deferiprone market. In addition, improved diagnostic capabilities and supportive orphan drug policies contribute significantly to market expansion. However, stringent safety monitoring requirements and potential adverse effects associated with deferiprone may restrict market growth. Moreover, ongoing research into expanded indications, combination therapies, and improved formulations offers remunerative opportunities for the expansion of the global deferiprone market.
Report Coverage & Details
Report Coverage
Details
Forecast Period
2024-2035
Base Year 2023
Market Size in 2023
$33.37 million
Market Size in 2033
$45.90 million
CAGR 3.2 %
No. of Pages in Report 280
Segments Covered Form, Application, Distribution Channel, and Region
Drivers • Increasing prevalence of iron overload disorders
• Introduction of generic products
• Increase in diagnosis and awareness of iron
overload disorders.
Opportunity
• Opportunity in untapped economies
Restraint • Adverse health effects and patient compliance
Want to Explore More, Connect to our Analyst –
https://www.alliedmarketresearch.com/connect-to-analyst/A324401
In clinical practice and hematology research, deferiprone is used to manage iron overload caused by repeated blood transfusions in patients with chronic anemias. Excess iron accumulation can damage vital organs such as the heart, liver, and endocrine glands. Regular monitoring through serum ferritin testing and advanced imaging techniques, including cardiac and hepatic MRI, enables clinicians to assess iron burden and tailor chelation therapy accordingly. These evidence-based treatment strategies improve long-term survival rates and reduce complications associated with transfusional iron overload.
The deferiprone market also extends beyond standard transfusion-related indications into broader iron dysregulation research. Ongoing clinical investigations are evaluating its role in combination regimens and potential benefits in non-transfusion-dependent thalassemia (NTDT). Continuous advancements in pharmacovigilance systems, patient monitoring protocols, and supportive care programs enhance treatment adherence and safety outcomes globally.
Segment Highlights
The tablets segment dominated the market share in 2023
On the basis of form, the tablets segment dominated the market share in 2023. This is attributed to the widespread preference for oral administration, ease of dosing, and improved patient compliance compared to parenteral chelation therapies. Tablet formulations offer convenient long-term management for patients requiring daily iron chelation. In addition, stable shelf life, simplified distribution, and established manufacturing capabilities further contribute to the expansion of this segment.
The transfusional iron overload segment accounted for the largest market share in 2023
By application, the transfusional iron overload segment dominated the market share in 2023. This is primarily due to the high prevalence of transfusion-dependent beta-thalassemia and sickle cell disease worldwide. Regular transfusions increase iron accumulation, necessitating continuous chelation therapy. Growing awareness, early diagnosis programs, and improved access to specialized hematology centers significantly contribute to segment growth.
Hospital pharmacies accounted for the largest market share in 2023
By distribution channel, hospital pharmacies dominated the market in 2023. This dominance is driven by the need for specialist supervision, routine blood monitoring, and structured treatment protocols. Drug stores, retail pharmacies, and online providers are also gaining traction, particularly for outpatient refills and long-term therapy access.
North America to maintain its dominance by 2033
Region wise, North America held the largest market share in 2023 and is expected to maintain its dominance during the forecast period. Advanced healthcare infrastructure, strong rare disease awareness, favorable regulatory policies, and availability of specialty treatment centers support regional growth. Meanwhile, Asia-Pacific is anticipated to witness significant expansion due to higher thalassemia prevalence and improving healthcare access.
For Purchase Related Queries/Inquiry –
https://www.alliedmarketresearch.com/purchase-enquiry/A324401
Key Players
- Mylan Pharmaceuticals Inc.
- Novartis AG
- GlaxoSmithKline plc,
- Amgen Inc.
- Sanofi SA
- Teva Pharmaceuticals Industries Ltd.
- Merck and Co.
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Pfizer Inc
Why Is Demand Increasing in the Deferiprone Market?
There is an increase in the demand for deferiprone due to the rising prevalence of transfusion-dependent anemias, growing awareness of iron overload complications, and improved access to diagnostic services. Conditions such as beta-thalassemia and sickle cell disease require frequent blood transfusions, which lead to excess iron accumulation in vital organs. Early diagnosis and routine monitoring of iron levels have significantly strengthened the need for effective iron chelation therapies, thereby fostering market growth.
The preference for oral iron chelators further boosts demand. Deferiprone offers convenient oral administration compared to parenteral alternatives, improving patient adherence and quality of life. This convenience is particularly important for pediatric and long-term patients who require continuous therapy.
The increasing global burden of rare hematological disorders also contributes substantially to market expansion. Growing screening programs, improved survival rates, and expanding healthcare coverage in emerging economies increase the treated patient pool.
Technological advancements in diagnostic imaging, including cardiac and liver MRI for iron quantification, support precise treatment planning and long-term disease management. Additionally, supportive orphan drug policies, patient assistance programs, and expanding specialty hematology centers continue to strengthen global demand for deferiprone therapies.
Get Customized Reports with your Requirements –
https://www.alliedmarketresearch.com/request-for-customization/A324401
Recent Development
- In recent years, Chiesi Farmaceutici S.p.A has strengthened its rare disease portfolio through continued regulatory expansions and lifecycle management strategies for deferiprone formulations. The company has focused on expanding geographic approvals and enhancing pharmacovigilance programs to reinforce patient safety and long-term treatment adherence in iron overload management.
- Apotex Inc. and Sun Pharmaceutical Industries Ltd. have emphasized the expansion of generic deferiprone offerings across emerging markets. These initiatives aim to improve affordability and increase patient access to oral iron chelation therapy, particularly in regions with a high prevalence of transfusion-dependent thalassemia.
- Cipla Limited has focused on strengthening its hematology portfolio by enhancing distribution partnerships and patient assistance programs to support long-term therapy adherence.
The report provides a detailed analysis of these key players in the global deferiprone market. These players have adopted different strategies such as expansion, product launch, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Trending Reports in Healthcare Industry:
Immunostimulant Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Dyspnea Treatment Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Breast Fillers Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Molecular Spectroscopy Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Wound Irrigation System Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Herb Extract Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Digital Radiology/Radiography Market – Global Opportunity Analysis and Industry Forecast, 2024-2035
Hearing Care Devices Market – Global Opportunity Analysis and Industry Forecast, 2024-2030
Intravenous (IV) Therapy and Vein Access Market – Global Opportunity Analysis and Industry Forecast, 2024-2030
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail themselves of an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of «Market Research Reports» and «Business Intelligence Solutions.» AMR has a targeted view to provide business insights and consulting to assist its clients in making strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies, and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality data and help clients in every way possible to achieve success. Each data presented in the reports published by us is extracted through primary interviews with top officials from leading companies in the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa1209 Orange Street,Corporation Trust Center,Wilmington, New Castle,Delaware 19801 USA.Toll Free: +1-800-792-5285Int’l: +1-503-894-6022UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: [email protected]
Web: https://www.alliedmarketresearch.com
Logo – https://mma.prnewswire.com/media/636519/5801121/Allied_Market_Research_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/deferiprone-market-to-reach-45-9-billion-by-2033-globally-at-3-2-cagr-allied-market-research-302689656.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…